Inactive Instrument

Lotus Pharmaceuticals, Inc. Share Price Other OTC

LTUS

US5457152032

Valuation: Lotus Pharmaceuticals, Inc.

Market Cap	97.36L 85.08L 78.51L 72.37L 1.36Cr 94Cr 1.39Cr 9.38Cr 3.69Cr 46Cr 3.66Cr 3.58Cr 158.07Cr	P/E 2009	3.88x	P/E 2010	4.84x
Enterprise Value	1.44Cr 1.26Cr 1.16Cr 1.07Cr 2.01Cr 138.51Cr 2.06Cr 14Cr 5.45Cr 68Cr 5.4Cr 5.28Cr 233.52Cr	EV / Sales 2009	1.02x	EV / Sales 2010	0.95x
Free-Float	99%	Yield 2009 *	-	Yield 2010	-

* Estimated data More valuation ratios

Latest news : Lotus Pharmaceuticals, Inc.

31/23/31	Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	MT
26/21/26	Thai oil firm PTT expands pharma business with $475 million Alvogen deal	RE
28/21/28	Lotus Pharmaceuticals : Temasek-backed Vertex expects at least $400 million in new S.E.Asia/India fund	RE
16/12/16	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS from LTUSE	CI
19/12/19	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS.E from LTUS	CI

More news

Press Releases: Lotus Pharmaceuticals, Inc.

30/12	Lotus Pharmaceutical Supports Street Medicine Program to Expand Access to Care for Those Most in Need	AQ
06/25/06	Lotus Enters License and Supply Agreement with Adalvo for Semaglutide injection	AQ
12/25/12	Lotus Pharmaceutical Achieves New First-Half Record in Revenue for 2025, While Q2 Impacted by FX and Timing of Lenalidomide Sales	AQ
21/25/21	Lotus announces FDA acceptance of Potential First-to-File ANDA Submission for Voclosporin soft gelatin capsules, a generic equivalent to Lupkynis	AQ
08/24/08	Lotus Achieves Second-Highest Quarterly Performance in Company History with 3Q24 Financial Results	AQ

More press releases

Managers and Directors: Lotus Pharmaceuticals, Inc.

Manager	Title	Age	Since
Georgene Rivers CEO	Chief Executive Officer	-	-

Director	Title	Age	Since
Georgene Rivers BRD	Director/Board Member	-	-

More insiders

Lotus Pharmaceuticals Inc is a company mainly engaged in development, manufacture, and sales of pharmaceuticals. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The Company's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The Company operated in two business segment Wholesales segment and Retail segment. The Company's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The Company mainly conducts its businesses in the domestic market and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Google lets you customize your preferred sources.

Choose MarketScreener

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LOTUS PHARMACEUTICALS, INC.	+41.51%	-18.92%	-	-	79.34L
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.90%	-0.15%	+13.46%	+79.34%	4.82TCr
OTSUKA HOLDINGS CO., LTD.	-0.23%	-1.65%	+65.14%	+115.81%	3.56TCr
CIPLA LIMITED	-0.76%	-1.44%	-4.30%	+37.38%	1.19TCr
ZYDUS LIFESCIENCES LIMITED	-0.88%	-0.62%	+16.38%	+89.65%	1.18TCr
KRKA, D. D.	+0.19%	+2.87%	+34.92%	+127.54%	930.92Cr
GEDEON RICHTER	-0.75%	-0.91%	+18.26%	+37.23%	690.82Cr
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-9.93%	+0.35%	-29.90%	+14.89%	612.82Cr
ONO PHARMACEUTICAL CO., LTD.	+3.37%	-0.10%	+49.31%	-4.38%	701.98Cr
GLENMARK PHARMACEUTICALS LIMITED	-2.25%	-2.08%	+0.40%	+218.27%	655.09Cr
Average	+2.94%	+0.06%	+18.19%	+79.53%	1.59TCr
Weighted average by Cap.	-0.88%	-0.42%	+25.98%	+86.36%

	2009	2010
Net sales	5.78Cr 5.05Cr 4.66Cr 4.3Cr 8.1Cr 556.86Cr 8.28Cr 56Cr 22Cr 272.73Cr 22Cr 21Cr 938.86Cr	7.27Cr 6.35Cr 5.86Cr 5.4Cr 10Cr 700.08Cr 10Cr 70Cr 28Cr 342.87Cr 27Cr 27Cr 1.18TCr
Net income	1.64Cr 1.44Cr 1.33Cr 1.22Cr 2.3Cr 158.25Cr 2.35Cr 16Cr 6.23Cr 78Cr 6.17Cr 6.04Cr 266.8Cr	1.44Cr 1.26Cr 1.16Cr 1.07Cr 2.02Cr 138.91Cr 2.07Cr 14Cr 5.47Cr 68Cr 5.42Cr 5.3Cr 234.21Cr
Net Debt	5.29 4.63 4.27 3.93 7.42 509.81 7.58 51.03 20.07 249.68 19.88 19.44 859.53	4.65 4.06 3.75 3.45 6.51 447.49 6.65 44.79 17.62 219.16 17.45 17.07 754.46

Lotus Pharmaceuticals, Inc. Share Price Other OTC

Stocks

LTUS

US5457152032

Pharmaceuticals

Valuation: Lotus Pharmaceuticals, Inc.

Latest news : Lotus Pharmaceuticals, Inc.

Press Releases: Lotus Pharmaceuticals, Inc.

Quotes and Performance

Managers and Directors: Lotus Pharmaceuticals, Inc.

Generic Pharmaceuticals

Financials

Company Profile